SYCP2 and breast carcinoma: A recent study suggested that SYCP2 was significantly upregulated in luminal B tumors compared with the adjacent normal tissues, and the upregulated SYCP2 expression might serve as an independent indicator of shorter overall survival in luminal A/B breast carcinoma (Wu and Tuo, 2019).